Janet Huffman - 11 Dec 2025 Form 4 Insider Report for ORAGENICS INC (OGEN)

Reporting relationship: CEO and CFO
Issuer ticker: OGEN
Reported as of: 11 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Dec 2025, 16:55:39 UTC
Prior SEC filing: 20 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Janet Huffman

Key filing fact

Janet Huffman filed Form 4 for ORAGENICS INC (OGEN) on 15 Dec 2025.

Key facts

This page summarizes Janet Huffman's Form 4 filing for ORAGENICS INC (OGEN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Dec 2025, 16:55.

Change

Previous filing in this sequence was filed on 20 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001866284 Primary reporting owner

Huffman Janet

Relationship: CEO and CFO
Address: 1990 MAIN STREET, SUITE 750, SARASOTA
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Janet Huffman
Signature date: 15 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGEN transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $0.9300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One third of the options vest on the first anniversary of the grant date and the remainder of the options subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.